BACKGROUND: IL-17 is an important cytokine signature of the TH differentiation pathway TH17. This T-cell subset is crucial in mediating autoimmune disease or antimicrobial immunity in animal models, but its presence and role in human disease remain to be completely characterized. OBJECTIVE: We set out to determine the frequency of TH17 cells in patients with cystic fibrosis (CF), a disease in which there is recurrent infection with known pathogens. METHODS: Explanted lungs from patients undergoing transplantation or organ donors (CF samples=18; non-CF, nonbronchiectatic samples=10) were collected. Hilar nodes and parenchymal lung tissue were processed and examined for TH17 signature by using immunofluorescence and quantitative real-time PCR. T cells were isolated and stimulated with antigens from Pseudomonas aeruginosa and Aspergillus species. Cytokine profiles and staining with flow cytometry were used to assess the reactivity of these cells to antigen stimulation. RESULTS: We found a strong IL-17 phenotype in patients with CF compared with that seen in control subjects without CF. Within this tissue, we found pathogenic antigen-responsive CD4+IL-17+ cells. There were double-positive IL-17+IL-22+ cells [TH17(22)], and the IL-22+ population had a higher proportion of memory characteristics. Antigen-specific TH17 responses were stronger in the draining lymph nodes compared with those seen in matched parenchymal lungs. CONCLUSION: Inducible proliferation of TH17(22) with memory cell characteristics is seen in the lungs of patients with CF. The function of these individual subpopulations will require further study regarding their development. T cells are likely not the exclusive producers of IL-17 and IL-22, and this will require further characterization.
BACKGROUND:IL-17 is an important cytokine signature of the TH differentiation pathway TH17. This T-cell subset is crucial in mediating autoimmune disease or antimicrobial immunity in animal models, but its presence and role in human disease remain to be completely characterized. OBJECTIVE: We set out to determine the frequency of TH17 cells in patients withcystic fibrosis (CF), a disease in which there is recurrent infection with known pathogens. METHODS: Explanted lungs from patients undergoing transplantation or organ donors (CF samples=18; non-CF, nonbronchiectatic samples=10) were collected. Hilar nodes and parenchymal lung tissue were processed and examined for TH17 signature by using immunofluorescence and quantitative real-time PCR. T cells were isolated and stimulated with antigens from Pseudomonas aeruginosa and Aspergillus species. Cytokine profiles and staining with flow cytometry were used to assess the reactivity of these cells to antigen stimulation. RESULTS: We found a strong IL-17 phenotype in patients with CF compared withthat seen in control subjects without CF. Within this tissue, we found pathogenic antigen-responsive CD4+IL-17+ cells. There were double-positive IL-17+IL-22+ cells [TH17(22)], and the IL-22+ population had a higher proportion of memory characteristics. Antigen-specific TH17 responses were stronger in the draining lymph nodes compared withthose seen in matched parenchymal lungs. CONCLUSION: Inducible proliferation of TH17(22) with memory cell characteristics is seen in the lungs of patients with CF. The function of these individual subpopulations will require further study regarding their development. T cells are likely not the exclusive producers of IL-17 and IL-22, and this will require further characterization.
Authors: Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo Journal: Nature Date: 2006-04-30 Impact factor: 49.962
Authors: Paul R Mangan; Laurie E Harrington; Darrell B O'Quinn; Whitney S Helms; Daniel C Bullard; Charles O Elson; Robin D Hatton; Sharon M Wahl; Trenton R Schoeb; Casey T Weaver Journal: Nature Date: 2006-04-30 Impact factor: 49.962
Authors: A Di Stefano; G Caramori; I Gnemmi; M Contoli; C Vicari; A Capelli; F Magno; S E D'Anna; A Zanini; P Brun; P Casolari; K F Chung; P J Barnes; A Papi; I Adcock; B Balbi Journal: Clin Exp Immunol Date: 2009-08 Impact factor: 4.330
Authors: Dawn C Newcomb; Weisong Zhou; Martin L Moore; Kasia Goleniewska; Gurjit K K Hershey; Jay K Kolls; R Stokes Peebles Journal: J Immunol Date: 2009-05-01 Impact factor: 5.422
Authors: Alberto Papi; Cinzia Maria Bellettato; Fausto Braccioni; Micaela Romagnoli; Paolo Casolari; Gaetano Caramori; Leonardo M Fabbri; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2006-02-16 Impact factor: 21.405
Authors: Marc Veldhoen; Richard J Hocking; Christopher J Atkins; Richard M Locksley; Brigitta Stockinger Journal: Immunity Date: 2006-02 Impact factor: 31.745
Authors: Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield Journal: Infect Immun Date: 2016-08-19 Impact factor: 3.441
Authors: Kathryn J Quigley; Catherine J Reynolds; Amelie Goudet; Eleanor J Raynsford; Ruhena Sergeant; Andrew Quigley; Stefan Worgall; Diana Bilton; Robert Wilson; Michael R Loebinger; Bernard Maillere; Daniel M Altmann; Rosemary J Boyton Journal: Am J Respir Crit Care Med Date: 2015-06-01 Impact factor: 21.405
Authors: Gregory S Whitehead; Hong Soon Kang; Seddon Y Thomas; Alexander Medvedev; Tadeusz P Karcz; Gentaro Izumi; Keiko Nakano; Sergei S Makarov; Hideki Nakano; Anton M Jetten; Donald N Cook Journal: JCI Insight Date: 2019-06-11
Authors: Dominik Hartl; Rabindra Tirouvanziam; Julie Laval; Catherine M Greene; David Habiel; Lokesh Sharma; Ali Önder Yildirim; Charles S Dela Cruz; Cory M Hogaboam Journal: J Innate Immun Date: 2018-02-13 Impact factor: 7.349